TransMedics Group, Inc. Common Stock
TMDX
$0.00
+7.61%
TransMedics Group, Inc. is a commercial-stage medical technology company focused on transforming organ transplant therapy through its proprietary Organ Care System (OCS). The company operates as a disruptive innovator in the medical device industry, offering a portable perfusion and monitoring platform that preserves donor organs in a near-physiologic state, addressing significant limitations of traditional cold storage. The current investor narrative is dominated by the company's transition to profitability and rapid revenue growth, though recent stock volatility suggests the market is grappling with valuation concerns and the sustainability of its expansion following a significant price correction from earlier highs.…
TMDX
TransMedics Group, Inc. Common Stock
$0.00
Investment Opinion: Should I buy TMDX Today?
Rating & Thesis: Hold. TMDX presents a 'show me' story where compelling fundamentals are overshadowed by technical damage and valuation concerns, requiring evidence of re-accelerating growth to justify a Buy rating. The analyst consensus leans bullish (e.g., Needham Buy, Evercore Outperform), but the lack of a clear average target price underscores the uncertainty.
Supporting Evidence: The Hold rating is supported by four key data points: 1) A forward P/E of 23.91x suggests the market still expects solid earnings growth. 2) Revenue growth, while decelerating to 32%, remains robust and well above likely sector medians. 3) The company generates substantial free cash flow ($133.6M TTM), funding its own growth. 4) The valuation has already compressed from historical extremes (P/E down from >76x), limiting near-term multiple contraction risk if execution holds.
Risks & Conditions: The two biggest risks are further growth deceleration below 25% and a break below the $60.11 technical support level. This Hold would upgrade to a Buy if revenue growth re-accelerates above 35% YoY or if the P/E multiple compresses below 20x on sustained earnings. It would downgrade to a Sell if quarterly revenue growth falls below 20% or if operating margins contract sequentially. Relative to its own history, the stock is fairly valued after its correction, but relative to the medical device sector, it remains overvalued, implying the market still expects superior growth.
Sign up to view all
TMDX 12-Month Price Forecast
The outlook for TMDX is balanced with high uncertainty. The company's fundamental execution is strong, marked by profitability and cash generation, but the investment case is clouded by decelerating growth and severe technical damage. The base case (55% probability) of stabilized growth and range-bound trading is most likely. The stance would upgrade to bullish on confirmation of re-accelerating revenue growth in the next two quarters or a decisive break above key technical resistance. It would turn bearish if the stock breaks below $60 support on worsening fundamentals.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on TransMedics Group, Inc. Common Stock's 12-month outlook, with a consensus price target around $0.00 and implied upside of — versus the current price.
Average Target
$0.00
5 analysts
Implied Upside
—
vs. current price
Analyst Count
5
covering this stock
Price Range
$0 - $0
Analyst target range
Analyst coverage for TMDX is limited, with only 5 analysts providing estimates, indicating it is a mid-cap stock with selective institutional interest. The consensus sentiment leans bullish, as evidenced by recent institutional ratings from firms like Needham (Buy), Evercore ISI (Outperform), and Piper Sandler (Overweight). However, the lack of a published average target price in the provided data prevents calculation of a precise implied upside or downside from the current price of $78.79. The target price range is also not available in the dataset. The recent pattern of analyst actions shows stability, with all ratings in the provided data being reiterations (e.g., Stifel Hold, JP Morgan Neutral) following the Q4 2025 earnings report in late February 2026, suggesting analysts are in a 'wait-and-see' mode after the stock's dramatic correction. The limited number of covering analysts can lead to higher volatility and less efficient price discovery, as the stock is more susceptible to shifts in sentiment from a small group of investors.
Bulls vs Bears: TMDX Investment Factors
The investment debate for TMDX centers on a clash between compelling fundamental progress and severe technical/valuation headwinds. The bull case is anchored in a proven, profitable growth story with a disruptive product, strong cash generation, and a valuation that has already corrected sharply. The bear case highlights the stock's deep downtrend, decelerating growth, premium sales multiple, and high volatility. Currently, the bearish evidence from price action and sentiment appears stronger, as the stock remains in a clear downtrend despite excellent fundamentals. The single most important tension is whether the company's 32% revenue growth can re-accelerate or stabilize to justify its elevated PS ratio of 6.83x, or if deceleration continues, triggering further multiple compression.
Bullish
- Exceptional Profitability Surge: The company achieved a dramatic transition to profitability, with Q4 2025 net income of $105.4 million and a net margin of 65.55%, up from just 5.64% a year ago. This demonstrates successful scaling of its disruptive technology and a powerful operating leverage story.
- Robust Revenue Growth Trajectory: Revenue growth remains strong at 32.18% YoY in Q4 2025, with sequential quarterly increases from $143.5M to $160.8M over the past year. This consistent execution validates commercial adoption of the Organ Care System in a large addressable market.
- Strong Balance Sheet and Cash Flow: The company boasts a robust current ratio of 7.14 and generated $133.6 million in trailing free cash flow. This provides ample internal funding for growth and reduces financial risk, supporting the transition from a speculative story to a sustainable business.
- Valuation Compression from Peaks: The trailing P/E of 21.73x is near the lower end of its historical range, having compressed significantly from over 76x in late 2024. This suggests much of the growth deceleration and multiple contraction risk may already be priced in after the 36% annual decline.
Bearish
- Severe Technical Downtrend and High Volatility: The stock is down 36.5% over the past year and 38.3% over six months, significantly underperforming the market. With a beta of 1.88, it is 88% more volatile than the market, indicating high risk and sensitivity to sentiment shifts.
- Revenue Growth Deceleration: While still strong at 32%, Q4's YoY revenue growth decelerated from 48% in the prior quarter. This sequential slowdown raises questions about the sustainability of hyper-growth and whether the company is approaching a plateau in its core market penetration.
- Premium Valuation on Sales Multiple: Despite the price correction, TMDX trades at a Price-to-Sales ratio of 6.83x, which is elevated for the medical devices sector. This premium valuation leaves the stock vulnerable to further multiple compression if growth expectations are not met.
- Limited Analyst Coverage and High Short Interest: With only 5 covering analysts, price discovery is less efficient and the stock is more susceptible to sentiment shifts from a small group. A short ratio of 3.88 indicates significant bearish bets, which can fuel sharp rallies but also reflects underlying skepticism.
TMDX Technical Analysis
The stock is in a pronounced downtrend, with a 1-year price change of -36.46% and a 6-month decline of -38.29%, significantly underperforming the broader market. As of the latest close of $78.79, the price is trading near the lower end of its 52-week range ($60.11 to $156.00), positioning it at approximately 19% above the 52-week low. This positioning suggests the stock is in a deep correction phase, potentially offering a value opportunity but also carrying the risk of further declines if the fundamental story deteriorates. Recent momentum shows a stark divergence, with a strong 1-month gain of 19.14% sharply contrasting the longer-term downtrend, indicating a potential technical rebound or short squeeze from deeply oversold levels. However, the 3-month performance remains deeply negative at -30.83%, highlighting that the recent bounce has only partially recovered from a severe sell-off, with a beta of 1.88 confirming the stock's high volatility, being 88% more volatile than the market. Key technical levels are clearly defined, with immediate support at the 52-week low of $60.11 and major resistance at the 52-week high of $156.00. A sustained break below the $60 support could signal a new leg down, while a recovery above the recent high near $150 would be needed to invalidate the primary downtrend. The high beta underscores the stock's sensitivity to market sentiment and company-specific news, demanding careful risk management.
Beta
1.88
1.88x market volatility
Max Drawdown
-58.8%
Largest decline past year
52-Week Range
$60-$156
Price range past year
Annual Return
-36.5%
Cumulative gain past year
| Period | TMDX Return | S&P 500 |
|---|---|---|
| 1m | +19.1% | +0.1% |
| 3m | -30.8% | +13.9% |
| 6m | -38.3% | +8.5% |
| 1y | -36.5% | +25.6% |
| ytd | -35.8% | +9.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TMDX Fundamental Analysis
Revenue growth is exceptionally strong but shows signs of sequential deceleration. The most recent quarterly revenue for Q4 2025 was $160.76 million, representing a robust year-over-year growth rate of 32.18%. However, this marks a deceleration from the 48% YoY growth seen in the prior quarter (Q3 2025 revenue of $143.82 million), suggesting growth may be plateauing at a high level. The revenue trajectory over the past four quarters shows consistent sequential increases, from $143.54M in Q1 to $160.76M in Q4, indicating ongoing commercial execution. Profitability has dramatically improved, with the company achieving substantial net income of $105.38 million in Q4 2025, translating to a net margin of 65.55%, though this was heavily influenced by a significant income tax benefit. The underlying operating profitability is solid, with an operating margin of 13.23% and a gross margin of 58.11% for the quarter. Comparing to the year-ago period (Q4 2024 net income of $6.86 million, net margin of 5.64%), the margin expansion is dramatic, signaling a successful transition to a profitable business model. The balance sheet and cash flow position are robust, with a strong current ratio of 7.14 and a manageable debt-to-equity ratio of 0.99. The company generated $133.59 million in trailing twelve-month free cash flow, providing ample internal funding for growth. The return on equity is exceptionally high at 40.22%, though this is inflated by the recent surge in profitability and a relatively low equity base, indicating highly efficient use of shareholder capital at this stage of growth.
Quarterly Revenue
$160764000.0B
2025-12
Revenue YoY Growth
+0.32%
YoY Comparison
Gross Margin
+0.58%
Latest Quarter
Free Cash Flow
$133589000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TMDX Overvalued?
Given the positive net income of $105.38 million in the latest quarter, the Price-to-Earnings (PE) ratio is the primary valuation metric. The trailing PE ratio is 21.73x, while the forward PE is 23.91x, based on estimated EPS. The slight premium on the forward multiple suggests the market expects earnings growth to continue, albeit at a moderated pace compared to the explosive profitability surge seen recently. Compared to industry averages, TransMedics trades at a significant premium based on its sales multiple. Its Price-to-Sales (PS) ratio of 6.83x is elevated for the medical devices sector, which often trades at lower multiples, indicating the market is pricing in superior growth prospects and its disruptive technology. The EV/EBITDA multiple of 27.72x further confirms this premium valuation, reflecting high expectations for future cash flow generation. Historically, the stock's valuation has compressed significantly from its peak. The current trailing PE of 21.73x is well below the historical highs seen in 2024 (e.g., 76.36x at the end of 2024) and even further below the extreme multiples from its pre-profitability phase. This places the valuation near the lower end of its own historical range, suggesting the market has already priced in a slowdown from the hyper-growth phase, potentially limiting further multiple contraction if execution remains solid.
PE
21.7x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -683x~311x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
27.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is valuation dependency on sustained high growth, as a deceleration from 32% could severely compress the premium PS multiple of 6.83x. While profitability has surged, the Q4 net margin of 65.55% was inflated by a one-time tax benefit; the underlying operating margin of 13.23% provides a more realistic baseline. The company carries a debt-to-equity ratio of 0.99, which is manageable but introduces financial leverage risk if interest rates remain elevated or cash flow generation falters.
Market & Competitive Risks: The stock faces significant market risk due to its high beta of 1.88, making it highly sensitive to broader market downturns and risk-off sentiment. Its premium valuation (EV/EBITDA of 27.72x) relative to the medical device sector creates compression risk if growth stock multiples contract or if a competitor emerges with a similar organ preservation technology. The limited analyst coverage (only 5 analysts) exacerbates volatility and can lead to inefficient price discovery during earnings periods.
Worst-Case Scenario: The worst-case scenario involves a combination of growth decelerating below 20%, a broader market sell-off impacting high-beta stocks, and a competitive or regulatory setback for the OCS platform. This could trigger a wave of analyst downgrades and force a re-rating towards sector-average multiples. The realistic downside could see the stock retest its 52-week low of $60.11, representing a potential loss of approximately -24% from the current price of $78.79. The historical max drawdown of -58.76% serves as a stark reminder of the stock's inherent volatility during adverse conditions.
FAQ
The key risks are: 1) Growth Deceleration Risk: Revenue growth slowed to 32% YoY from 48%, and further slowdown could crush its premium valuation. 2) Volatility and Market Risk: With a beta of 1.88, the stock is highly sensitive to market downturns, as evidenced by its 38% six-month decline versus the market's gain. 3) Competitive/Regulatory Risk: As a single-product company in medical devices, its success depends entirely on the OCS platform's adoption and lack of disruptive competition. 4) Sentiment Risk: Limited analyst coverage (5 analysts) and high short interest (short ratio 3.88) can lead to exaggerated price swings on news.
The 12-month forecast for TMDX is bifurcated with a base case target range of $90-$120 (55% probability). The bull case (25% probability) targets $140-$156 if growth re-accelerates, while the bear case (20% probability) sees a drop to $60-$80 if growth decelerates sharply. The most likely scenario is the base case, which assumes revenue growth stabilizes around 25-30% and the stock's valuation multiples hold steady as the company demonstrates consistent profitability. The key assumption behind this forecast is that the company avoids further significant growth deceleration in the next two quarters.
TMDX's valuation presents a mixed picture. It is relatively undervalued compared to its own history, with a trailing P/E of 21.73x well below its peak of over 76x. However, it remains overvalued relative to the broader medical device sector based on its Price-to-Sales ratio of 6.83x, which is elevated for the industry. The forward P/E of 23.91x indicates the market is still pricing in future earnings growth. Overall, the stock is fairly valued given its current growth rate of 32% and profitability profile, but it carries a premium that requires sustained execution to justify.
TMDX is a high-risk, high-potential reward stock that may be suitable for a specific investor profile. For aggressive growth investors with a long-term horizon and high volatility tolerance, the current price near a 52-week low could represent an entry point after a 36% decline. The company has strong fundamentals, including 32% revenue growth and robust free cash flow. However, it is not a good buy for conservative investors due to its high beta of 1.88, premium valuation (PS ratio 6.83x), and the risk of further growth deceleration. A good buy is conditional on the investor's belief that revenue growth will stabilize or re-accelerate from its current level.
TMDX is primarily suitable for a long-term investment horizon of 3-5 years, not short-term trading. Its high beta of 1.88 and recent volatility make it a poor candidate for short-term trades unless based on precise technical timing. The long-term thesis depends on the global adoption of its OCS technology, which will take years to unfold. The company's transition to profitability and strong cash flow generation support a long-term holding period, allowing investors to ride out volatility. A minimum holding period of 18-24 months is suggested to allow for the next phase of commercial execution and potential regulatory milestones.